CPADS

Cell permeable peptides as drug delivery system: a way towards innovative therapeutic strategies for neurodegeneration

Coordinatore	UNIVERSITA DEGLI STUDI DI MILANO    more  Organization address address: Via Festa Del Perdono 7 city: MILANO postcode: 20122 contact info Titolo: Prof. Nome: Monica Cognome: Di Luca Email: send email Telefono: +39 02 50318374 Fax: +39 02 50318284
Nazionalità Coordinatore	Italy [IT]
Totale costo	904˙965 €
EC contributo	904˙965 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2007-3-1-IAPP
Funding Scheme	MC-IAPP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-03-01   -   2012-02-29

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITA DEGLI STUDI DI MILANO  Organization address address: Via Festa Del Perdono 7 city: MILANO postcode: 20122 contact info Titolo: Prof. Nome: Monica Cognome: Di Luca Email: send email Telefono: +39 02 50318374 Fax: +39 02 50318284	IT (MILANO)	coordinator	0.00
2	CF CONSULTING FINANZIAMENTI UNIONE EUROPEA SRL  Organization address address: Via Giuseppe Mussi 1 city: MILANO postcode: 20154 contact info Titolo: Ms. Nome: Carla Cognome: Finocchiaro Email: send email Telefono: 39023108331 Fax: +39 02 33614064	IT (MILANO)	participant	0.00
3	CIS BIO INTERNATIONAL SAS  Organization address address: Rn Saclay 306 city: GIF SUR YVETTE CEDEX postcode: 91192 contact info Titolo: Mr. Nome: Gerard Cognome: Mathis Email: send email Telefono: +33 466796771	FR (GIF SUR YVETTE CEDEX)	participant	0.00
4	ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI  Organization address address: Via Giuseppe La Masa 19 city: MILANO postcode: 20156 contact info Titolo: Ms. Nome: Maria Grazia Cognome: Pezzoni Email: send email Telefono: +39 02 39104304 Fax: +39 02 39009728	IT (MILANO)	participant	0.00
5	XIGEN SA  Organization address address: rue des Terraux 17 city: LAUSANNE postcode: 1003 contact info Titolo: Mr. Nome: Elmar Cognome: Schárli Email: send email Telefono: +41 026 492 5070 Fax: +41 026 492 5671	CH (LAUSANNE)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Peptides and small molecules able to modulate protein-protein interaction as well as intracellular pathways leading to neurodegeneration and cell death hold a great potential as innovative therapeutic strategies with which to probe and manipulate biological pathways. The need to deliver these biologically active agents into cells has encouraged to develop various transducing vectors. In this view, cell permeable peptides conjugates represent a novel, versatile and extremely powerful way of blocking the propagation of intracellular signaling events or intracellular protein complexes, thus being an useful tools for both creating innovative animal models and to design innovative therapeutic strategies. The project aims to foster a dynamic pathway between academic research organizations and private commercial enterprises based on a longer term co-operation programme in the field of innovative therapeutic strategies for neurodegenerative disorders. The project will focus on the following specific objectives: i) Identify and verify appropriate targets, making use of innovative animal models to develop blocking/inhibitory small molecules; ii) Design appropriate cell permeable peptides and develop proteases resistant vectors. The projects goal will be sustained by concrete transfer of knowledge assured by bidirectional secondments and recruitment of external expertise. Further, the strong complementarities of competencies of the partners involved will be instrumental: through knowledge sharing and intersectorial mobilities the project will lead to develop new generation of drugs tackling with unprecedented specificity pathways of degeneration in neuronal cells. The intersectorial two-ways transfer of knowledge proposed in the project will strongly accelerate the all process from ideation to application of novel potential drugs for neurodegeneration and will speed up the advancement of research capability and the competitiveness of the partners involved.'